Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 11.2% in October

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 3,001,500 shares, a growth of 11.2% from the October 15th total of 2,699,000 shares. Based on an average daily trading volume, of 1,100 shares, the days-to-cover ratio is presently 2,728.6 days.

Innovent Biologics Price Performance

Shares of IVBXF stock opened at $4.58 on Monday. The stock has a 50-day moving average of $5.51 and a 200-day moving average of $5.19. Innovent Biologics has a 1-year low of $3.83 and a 1-year high of $6.40.

About Innovent Biologics

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.